TScan launches Phase 3 ALLOHA-2 with $128m in cash and a looming funding gap

TScan Therapeutics, Inc. (Nasdaq: TCRX) has infused the first patient in the pivotal Phase 3 ALLOHA-2 trial of TSC-101, moving its lead engineered T-cell therapy into a study designed to determine whether it can prevent relapse after allogeneic stem cell transplantation. The trial is enrolling patients with acute myeloid leukemia and myelodysplastic syndromes across the United States, with topline results anticipated in mid-2028. TScan shares closed July 29 at approximately $0.74, down about 4%, giving the company a market capitalization near $96.6 million. That valuation is close to the company’s March net cash position before accounting for subsequent spending, even though management’s stated cash runway reaches only into the second half of 2027. The investment case therefore depends on whether TScan can finance ALLOHA-2 through its readout, scale a patient-specific manufacturing model and prove that early donor-chimerism gains translate into fewer relapses and longer survival.

ALLOHA-2 must turn early donor-chimerism gains into fewer AML and MDS relapses

TSC-101 is designed to eliminate residual recipient blood cells after an allogeneic hematopoietic cell transplant. The therapy is manufactured from T cells collected from the same healthy donor who provides the transplant and is genetically engineered to recognize the HA-2 antigen when it is presented by HLA-A*02:01. Because the donor’s replacement blood cells lack the targeted HLA combination, TScan intends the therapy to attack remaining recipient-derived cells, including malignant cells, while sparing the new donor-derived blood system.

ALLOHA-2 uses biological assignment rather than conventional randomization. Patients who carry HLA-A02:01 and have an appropriate donor are assigned to receive TSC-101, while HLA-A02:01-negative patients and positive patients without a suitable donor enter the transplant-only control group. Every participant receives reduced-intensity conditioning followed by standard-of-care transplantation, while the treatment group receives two TSC-101 infusions after successful engraftment.

Relapse-free survival is the primary endpoint, with overall survival and event-free survival among the principal secondary measures. That endpoint structure is commercially important because it requires TSC-101 to demonstrate a clinical outcome rather than relying only on donor chimerism, a laboratory measurement showing how completely donor cells have replaced recipient cells.

The supporting Phase 1 data are encouraging but small. In Cohort C of the ALLOHA study, TScan successfully manufactured TSC-101 for 17 of 19 enrolled patients. Fourteen proceeded to transplantation and received a first infusion, with 11 reaching complete donor chimerism approximately three weeks later and two additional patients approaching complete chimerism. Ten patients received a planned second infusion, and all five who had been assessed after that second dose had reached complete chimerism.

Those results show that TSC-101 can produce the biological effect the company intended, but they do not establish that it prevents cancer recurrence. Chimerism may be associated with relapse risk, yet ALLOHA-2 must demonstrate that actively eliminating recipient cells improves outcomes across a much larger group without adding enough toxicity to undermine transplantation benefits.

The Phase 1 population also creates a difficult comparison because patients were not conventionally randomized. HLA status and donor suitability determine treatment assignment, potentially producing differences between the experimental and control groups that affect relapse independently of TSC-101. The Phase 3 analysis will need to show that baseline disease severity, transplant characteristics and other prognostic factors are sufficiently balanced or statistically addressed.

The company expects the pivotal readout in mid-2028. That schedule leaves almost two years for enrollment, transplantation, engraftment, cell-therapy administration and the accumulation of relapse events. The first infusion confirms that the trial is operational, but recruitment speed and transplant timing will determine whether the projected readout remains achievable.

Why TScan’s current cash runway may not reach the planned mid-2028 trial readout

TScan reported $128.1 million in cash and cash equivalents at March 31, excluding $5 million of restricted cash. Management said those resources were expected to fund its operating plan into the second half of 2027, meaning the existing runway ends before the anticipated ALLOHA-2 topline result.

The company generated only $1 million in first-quarter revenue, primarily from research activity under its Amgen collaboration. Research and development expenses totaled $21.9 million, general and administrative expenses reached $8.2 million and the quarterly net loss was $28.7 million. TScan remains a development-stage biotechnology company without product revenue, leaving future operations dependent on existing cash, collaboration income, debt or additional equity financing.

TScan had $32.5 million in term-loan principal outstanding at the end of March. The loan’s effective interest rate was 8.46%, and the agreement places restrictions on transactions including additional borrowing, asset sales, dividends and certain investments. Cash minus outstanding principal was therefore roughly $95.6 million at the end of March, close to the company’s July 29 market capitalization, although that comparison excludes subsequent cash use, other liabilities and the economic impact of restricted cash.

The market is effectively assigning limited value to TScan’s pipeline beyond its balance-sheet assets, but that does not automatically make the equity inexpensive. The cash is intended to finance a pivotal cell-therapy trial, follow-on hematology candidates and earlier solid-tumor and autoimmune research. By the time ALLOHA-2 reports, a meaningful portion of the March balance is likely to have been consumed.

TScan has already reduced spending by prioritizing its hematologic malignancy program. First-quarter research expenses declined from $29.8 million a year earlier to $21.9 million, partly because of lower purchases of supplies and consumables. This prioritization protects the TSC-101 program but also shows that capital constraints are shaping the broader pipeline.

The company’s share structure creates additional dilution considerations. At March 31, TScan had approximately 60.1 million common shares outstanding and pre-funded warrants covering another 69.8 million shares. Including those warrants, the pro forma share count was approximately 129.9 million. The warrants have a nominal exercise price and should be considered when assessing ownership dilution and market capitalization.

A financing before the mid-2028 readout appears possible unless TScan reduces spending further, secures collaboration funding or accesses additional debt. The timing and size of any transaction will depend on enrollment progress, updated Phase 1 data, broader biotechnology market conditions and the share price. Raising equity at less than $1 per share could create substantial dilution, while waiting too long could weaken negotiating leverage.

The company may also try to use upcoming milestones to improve financing terms. Updated Cohort C results, progress from the follow-on TSC-102 programs and visible ALLOHA-2 enrollment could strengthen investor confidence before the runway becomes critical. The financial challenge is to reach those catalysts without allowing liquidity concerns to overshadow the clinical program.

Patient-specific TSC-101 production could become either a competitive advantage or a bottleneck

TSC-101 is donor-derived but remains patient-specific. Manufacturing begins with cells collected from each patient’s transplant donor, after which those cells must be engineered, expanded, tested and delivered on a schedule coordinated with the transplant procedure. This differs from a fully off-the-shelf therapy that can be stored and shipped from inventory.

Cohort C provided an early commercial-readiness test. TScan achieved manufacturing success for 17 of 19 enrolled patients, or approximately 90%. That result supported the transition to Phase 3, but it also means two enrolled patients did not receive a successfully manufactured product. In a registrational and commercial setting, manufacturing failures can delay treatment, reduce trial efficiency and impose costs even when a patient never receives therapy.

The production timeline must also match a medically complex transplant pathway. Three of the 19 Cohort C patients did not proceed to transplantation for clinical reasons, showing how disease progression and changes in patient condition can disrupt the process even when manufacturing succeeds. Fourteen patients ultimately received the first TSC-101 infusion.

TScan is evaluating automated manufacturing with Cellares as a possible route to commercial scale. The collaboration is assessing whether TSC-101 production and release testing can be transferred to automated, closed-system platforms intended to reduce manual labor, process variability and geographic capacity constraints. The agreement is an evaluation rather than confirmation that Cellares will manufacture commercial supply or that automation will deliver the proposed cost savings.

Commercial economics will depend on manufacturing success rates, turnaround time, labor requirements and the number of production sites needed to support transplant centers. A healthy donor can provide starting material of better quality than heavily pretreated cancer patients often used for autologous cell therapies, potentially improving manufacturing consistency. The product still requires individual coordination for every recipient and cannot be distributed as a single universal batch.

The treatment’s position after transplantation may make the commercial pathway more concentrated than other oncology launches. Allogeneic transplants are performed at specialized centers with established cellular-therapy infrastructure. TScan would not need to reach every community oncology practice, but it would need to integrate manufacturing, scheduling, patient identification and reimbursement into a demanding transplant workflow.

A therapy that meaningfully reduces relapse could justify substantial pricing because transplantation is expensive and recurrent AML or MDS carries high medical and mortality costs. TScan will still need health-economic evidence demonstrating that the added cell-therapy expense is offset by fewer relapses, hospitalizations, salvage treatments and repeat transplants.

HLA restrictions make TScan’s follow-on therapies central to the commercial opportunity

TSC-101 cannot treat every patient undergoing transplantation for AML or MDS. Eligibility depends on the patient carrying HLA-A*02:01 and having a donor with the required genetic mismatch. Patients who lack that HLA type or cannot identify an appropriate donor cannot receive the product under the current strategy.

TScan is developing TSC-102-A01 and TSC-102-A03 to reach patients carrying HLA-A01:01 and HLA-A03:01. The company has stated that these follow-on candidates could approximately double the number of transplant patients addressable by its TCR-T approach. Both programs have received investigational clearance, with Phase 1 development planned for the second half of 2026.

The broader strategy resembles a portfolio of genetically matched therapies rather than one universally applicable product. If successful, TScan could screen patients by HLA type and provide the corresponding engineered T-cell candidate. That model increases addressable market coverage but also requires separate clinical programs, manufacturing processes, regulatory submissions and commercial inventory planning for each therapy.

TSC-101 is therefore both a product candidate and a validation test for the platform. A successful ALLOHA-2 result could support confidence that TScan can use donor-recipient genetic differences to remove residual disease after transplantation. A failure caused by weak relapse prevention, manufacturing problems or unfavorable safety could affect the perceived value of the follow-on hematology programs even though they target different HLA groups and antigens.

The same platform is being explored beyond blood cancers, but TScan has shifted its solid-tumor strategy toward earlier in vivo engineering work and is developing preclinical approaches in autoimmune disease. Those programs offer longer-term optionality but are unlikely to change the company’s near-term financial outlook. TSC-101 and ALLOHA-2 remain the primary drivers of valuation.

The July 29 milestone confirms that TScan has crossed from planning into pivotal execution. The market now has a defined clinical endpoint and an expected readout window, but also a visible financing gap. The company must show that its early biological data can become a durable reduction in relapse while demonstrating that individualized manufacturing can function reliably across a nationwide Phase 3 network.

Key takeaways from TSC-101’s Phase 3 launch and TScan’s investment outlook

• TScan has infused the first patient in the pivotal ALLOHA-2 trial, with topline relapse-free survival data anticipated in mid-2028.
• ALLOHA-2 will test TSC-101 after standard-of-care transplantation against transplantation alone in patients with AML or MDS.
• Phase 1 Cohort C showed that 11 of 14 treated patients reached complete donor chimerism within approximately three weeks, but chimerism is not proof that relapse will be prevented.
• The company achieved approximately 90% manufacturing success in Cohort C, supporting Phase 3 readiness while also highlighting the risk of patient-specific production failures.
• TScan held $128.1 million in unrestricted cash at March 31 and expects its current resources to last into the second half of 2027, before the planned pivotal readout.
• First-quarter net loss reached $28.7 million, while revenue was only $1 million, leaving the company dependent on financing or partnership capital.
• TScan’s July 29 market capitalization of approximately $96.6 million was close to its March cash balance after subtracting term-loan principal, but ongoing clinical spending reduces the significance of that comparison.
• Nearly 70 million pre-funded warrants expand TScan’s effective share base and should be included when evaluating dilution and valuation.
• The Cellares automation evaluation could improve commercial manufacturing economics, but it has not yet established a finalized commercial production network.
• Follow-on TSC-102 candidates are strategically important because TSC-101’s HLA restriction limits the eligible transplant population.